The global demand for Neuroendocrine Tumors Market is presumed to reach the market size of nearly USD 7.77 BN by 2030 from USD 3.3 BN in 2022 with a CAGR of 11.29% under the study period 2023 - 2030.
Neuroendocrine tumors (NETs) are a type of rare neoplasm that can develop in various organs throughout the body. They arise from cells of the neuroendocrine system, which is responsible for producing hormones and regulating bodily functions. Neuroendocrine cells are found in organs such as the lungs, gastrointestinal tract, pancreas, and adrenal glands.
There has been an increase in the incidence and prevalence of neuroendocrine tumors (NETs) globally, attributed to improved detection methods and increased awareness. This growing patient population fuels the demand for diagnostic tests, treatment options, and supportive care. The advancements in diagnostic technologies, such as PET scans and molecular biomarkers, have enhanced the accuracy of its diagnosis and staging. These innovations enable early detection, precise localization, and personalized treatment approaches. The treatment landscape for neuroendocrine tumors (NETs) has expanded with the introduction of targeted therapies like somatostatin analogues, PRRT, and tyrosine kinase inhibitors. These novel treatments provide healthcare professionals with more options, driving the market growth. Supportive government initiatives, including research funding, policy implementation, and reimbursement support, also contribute to market growth by creating a favourable environment for the development and commercialization of neuroendocrine tumors (NETs) treatments. Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare organizations accelerate research and development efforts, leading to innovative therapies and market expansion. Lastly, patient advocacy and support groups play a vital role in raising awareness, providing education, and advocating for improved access to diagnosis and treatment. Their efforts contribute to increased recognition of neuroendocrine tumors (NETs) as a distinct disease entity, further driving the market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of neuroendocrine tumors. The growth and trends of neuroendocrine tumors industry provide a holistic approach to this study.
This section of the neuroendocrine tumors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Classification
By Site
By Grade
By Type
By Route Of Administration
By End User
By Distribution Channel
This section covers the regional outlook, which accentuates current and future demand for the Neuroendocrine Tumors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the neuroendocrine tumors market include F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Viatris Inc., Thermo Fisher Scientific Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, LUPIN, Exact Sciences Corporation, Pfizer Inc., Ipsen Pharma, Advanced Accelerator Applications (a subsidiary of Novartis AG), BioSynthema Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Bionano Genomics, callistopharma, Illumina, Inc., GlaxoSmithKline plc, Hutchison China MediTech Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . NEUROENDOCRINE TUMORS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Classification
3.7.2 Market Attractiveness Analysis By Site
3.7.3 Market Attractiveness Analysis By Grade
3.7.4 Market Attractiveness Analysis By Type
3.7.5 Market Attractiveness Analysis By Route Of Administration
3.7.6 Market Attractiveness Analysis By End User
3.7.7 Market Attractiveness Analysis By Distribution Channel
3.7.8 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL NEUROENDOCRINE TUMORS MARKET SALES BY CLASSIFICATION
5.1 Overview by Classification
5.2 Historical and Forecast Sales Data
5.3 Analysis by Classification
5.4 Functional Net Historic and Forecast Sales by Regions
5.5 Non-Functional Net Historic and Forecast Sales by Regions
6 . GLOBAL NEUROENDOCRINE TUMORS MARKET ANALYSIS BY SITE
6.1 Overview by Site
&n ...